Coya Therapeutics annual stock-based compensation
2021
2022
2023
2024
2025
Coya Therapeutics Stock-Based Compensation Growth & History (COYA)
Coya Therapeutics's stock-based compensation was $4.3M for fiscal 2025.
View full Coya Therapeutics company overviewCoya Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.3M | $1.6M | +61.08% |
| 2024 | 2024-12-31 | $2.7M | $1.8M | +205.36% |
| 2023 | 2023-12-31 | $872,248 | $664,902 | +320.67% |
| 2022 | 2022-12-31 | $207,346 | −$25,876 | −11.10% |
| 2021 | 2021-12-31 | $233,222 | — | — |
Coya Therapeutics quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $943,911 | −$91,802 | −8.86% |
| Q1 2026 | 2026-03-31 | $2.2M | $1.1M | +103.27% |
| Q4 2025 | 2025-12-31 | $1.1M | $313,079 | +39.60% |
| Q3 2025 | 2025-09-30 | $1.1M | $295,886 | +38.18% |
| Q2 2025 | 2025-06-30 | $1.0M | $373,392 | +56.38% |
| Q1 2025 | 2025-03-31 | $1.1M | $644,419 | +147.92% |
| Q4 2024 | 2024-12-31 | $790,549 | $552,550 | +232.16% |
| Q3 2024 | 2024-09-30 | $775,006 | $512,254 | +194.96% |
| Q2 2024 | 2024-06-30 | $662,321 | $471,211 | +246.57% |
| Q1 2024 | 2024-03-31 | $435,663 | $255,276 | +141.52% |
| Q4 2023 | 2023-12-31 | $237,999 | $166,570 | +233.20% |
| Q3 2023 | 2023-09-30 | $262,752 | $192,918 | +276.25% |
| Q2 2023 | 2023-06-30 | $191,110 | $146,452 | +327.94% |
| Q1 2023 | 2023-03-31 | $180,387 | $158,962 | +741.95% |
| Q4 2022 | 2022-12-31 | $71,429 | — | — |
| Q3 2022 | 2022-09-30 | $69,834 | — | — |
| Q2 2022 | 2022-06-30 | $44,658 | — | — |
| Q1 2022 | 2022-03-31 | $21,425 | — | — |
Coya Therapeutics stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Coya Therapeutics's stock-based compensation increased from $233,222 to $4.3M, a change of $4.1M. The latest reported quarter, Q2 2026, shows $943,911.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics source filings ↗